No Data
Hanyu Pharmaceutical: 2024 Annual Report
Hanyu Pharmaceutical: Report for the first quarter of 2025
Hanyu Pharmaceutical: 2024 Annual Report Summary
Hybio Pharmaceutical (300199.SZ): In the first quarter, net income was 69.8684 million yuan, turning a loss into a profit year-on-year.
Gelonghui, April 25th丨Hybio Pharmaceutical (300199.SZ) announced its report for the first quarter of 2025, achieving revenue of 0.31 billion yuan, a year-on-year increase of 106.29%; the net income attributable to shareholders of the listed company was 69.8684 million yuan, turning from loss to profit year-on-year; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 65.55 million yuan; and the basic EPS was 0.08 yuan.
Multiple stocks hit the涨停, the CRO Industry is recovering! Asymchem Laboratories achieved a new high in net income in Q1.
The performance of multiple businesses has greatly increased.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Subdued Growth No Barrier To Hybio Pharmaceutical Co., Ltd. (SZSE:300199) With Shares Advancing 28%
